ClinicalTrials.gg
CompletedNCT05277571Updated Jul 22, 2026

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

A Phase 1/2 interventional study of UCB1381 and Placebo in Atopic Dermatitis, sponsored by UCB Biopharma SRL. Completed at 16 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1/2, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
254th of 544
109 · median 96
Started
2022
with 44 others
Phase 1/2
15 of 639
none open now
Registered
456th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 254th largest by enrollment of the 544 interventional ones that give a count, is one of 45 that started in 2022, is one of 15 in phase 1/2, and was the 456th registered.

Dermatitis, Atopic

1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic dermatitis
  • Phase 1/2A
  • Healthy study participants
  • Patients
  • UCB1381
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A Healthy study participants

  • Participant must be 18 to 55 years of age inclusive at the time of signing the form (ICF)
  • Participant must be overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
  • Participant has a (BMI) within the range 18 to 30 kg/m2 (inclusive)
  • Participant can be male or female and must agree to use

Part B Participants with moderate to severe Atopic dermatitis (AtD)

  • Participant must be 18 to 65 years of age inclusive at the time of signing the ICF
  • Participant has moderate or severe AtD that has been present for at least 12 months prior to initiating the study (signing of the ICF) and with:
  • A validated Investigator Global Assessment (vIGA) score ≥3 at Screening and Baseline
  • An Eczema Area and Severity Index (EASI) score of ≥14 at Screening and ≥16 at Baseline
  • Pruritis Numerical Rating Scale (NRS) ≥3 at Screening and Baseline
  • ≥10 % body surface area (BSA) of AtD involvement at Screening and Baseline
  • Either documented recent history (within 6 months before the Screening Visit) of inadequate response to treatment with topical medications (regular use of topical [TCS] or topical calcineurin inhibitors [TCIs]) or when topical treatments are confirmed to be otherwise medically inadvisable (eg, because of important side effects or safety risks)
  • Participant has a BMI within the range 18 to 35 kg/m2 (inclusive)

Exclusion criteria

Exclusion Criteria:

Part A Healthy study participants

  • Participant has a history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, (ECG), or vital sign that, in the opinion of the investigator, could significantly alter the absorption, metabolism, or elimination of drugs; constitute a risk when taking the study intervention; or interfere with the interpretation of data
  • Participant has a known to any components of the medicinal product (IMP) or other biologic drugs (including humanized monoclonal antibodies (mAbs)), drug allergies, or history of severe adverse reactions after drug administration
  • Participant has a past history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
  • Participant has previously been randomized in this study
  • Participant has participated in another study of an IMP or has received any biologic agent (such as mAbs, including marketed drugs and including biologic agents that target interleukin (IL)-13 or IL-22) within the 30 days prior to Screening or 5 half-lives (whichever is longer), if this information can be validated by the investigator

Part B Participants with moderate to severe AtD

  • Participant has a history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, electrocardiogram (ECG), or vital sign that, in the opinion of the investigator, could significantly alter the absorption, metabolism, or elimination of drugs; constitute a risk when taking the study intervention; or interfere with the interpretation of data
  • Participant has a known hypersensitivity to any components of the IMP or other biologic drugs (including humanized mAbs), clinically significant drug allergies, or history of severe adverse reactions after drug administration
  • Participant has a past history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
  • Participant has had pharmaceutically active topical therapies for AtD (including mild topical (TCS)) within 2 weeks of the Baseline Visit (corticosteroids, cyclosporin or other calcineurin inhibitors [eg, tacrolimus, pimecrolimus])
  • Participant has received phototherapy or systemic non-biologic therapies for AtD within 4 weeks of the Baseline Visit (including moderate/strong corticosteroids, cyclosporine A or other calcineurin inhibitors, mycophenolate mofetil, azathioprine, methotrexate, or any alternative medicine for AtD, eg, traditional Chinese medicine)
  • Participant has previously used a biologic that affects IL-13 or IL-22 pathways, or any JAK inhibitor (including marketed and/or experimental treatments), within 30 days or 5 half-lives (whichever is longer) of the Baseline Visit. Previous use of biologics affecting IL-13 or IL-22 pathways is only accepted if treatment was stopped due to reasons other than inadequate efficacy and safety (eg, administrative reasons, poor convenience, poor access to drug)
  • Participant has received any prescription or nonprescription medicines, including over the counter remedies and herbal and dietary supplements (other than vitamins within recommended daily dose limits) within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to the Baseline Visit, other than (oral, implant, or intrauterine devices) or occasional use of analgesics such as paracetamol (acetaminophen, with or without caffeine, with a maximal dose of 4g/day and 10g/14 days) or intranasal corticosteroids for seasonal rhinitis or inhaled bronchodilators and low dose inhaled corticosteroids for mild asthma. In case of uncertainty, the UCB Development Physician should be consulted
  • Participant has previously been randomized in this study
  • Participant has participated in previous studies with a biologic that affects IL-13 or IL-22 pathways, or any JAK inhibitor (including marketed and/or experimental treatments), within 30 days or 5 half-lives (whichever is longer) of the Baseline Visit. Previous use of biologics affecting IL-13 or IL-22 pathways is only accepted if treatment was stopped due to reasons other than inadequate efficacy and safety (eg, administrative reasons, poor convenience, poor access to drug)
  • Participant has participated in another study of an IMP within 30 days or 5 half-lives (whichever is longer) of the Baseline Visit or is currently participating in another study of an IMP
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    UCB1381 dosing regime 1 in Part A

    Participants will be randomized to receive a single dose UCB1381 intravenously (iv).

    Biological: UCB1381

  • Experimental
    UCB1381 dosing regime 2 in Part A

    Participants will be randomized to receive a single dose UCB1381 intravenously (iv).

    Biological: UCB1381

  • Experimental
    UCB1381 dosing regime 3 in Part A

    Participants will be randomized to receive a single dose UCB1381 intravenously (iv).

    Biological: UCB1381

  • Experimental
    UCB1381 dosing regime 4 in Part A

    Participants will be randomized to receive a single dose UCB1381 intravenously (iv).

    Biological: UCB1381

  • Experimental
    UCB1381 dosing regime 5 in Part A

    Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).

    Biological: UCB1381

  • Experimental
    UCB1381 dosing regime 6 in Part A

    Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).

    Biological: UCB1381

  • Experimental
    UCB1381 dosing regime 7 in Part A

    Participants will be randomized to receive a single dose UCB1381 intravenously (iv).

    Biological: UCB1381

  • Experimental
    UCB1381 dosing regime 8 in Part A

    Participants will be randomized to receive a single dose UCB1381 intravenously (iv).

    Biological: UCB1381

  • Experimental
    UCB1381 dosing regime 9 in Part B

    Participants will be randomized to receive repeated doses UCB1381 intravenously (iv).

    Biological: UCB1381

  • Placebo comparator
    Placebo iv Arm Part A

    Participants will be randomized to receive a single dose of placebo iv to maintain the blinding.

    Drug: Placebo

  • Placebo comparator
    Placebo sc Arm Part A

    Participants will be randomized to receive a single dose of placebo sc to maintain the blinding.

    Drug: Placebo

  • Placebo comparator
    Placebo iv Arm Part B

    Participants will be randomized to receive repeated doses of placebo iv to maintain the blinding.

    Drug: Placebo

Interventions

  • BiologicalUCB1381

    UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

  • DrugPlacebo

    Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.

06

What researchers measure

Primary outcomes

  1. Incidents of treatment-emergent adverse events (TEAEs) from Baseline through the End of Study (EOS) Visit (Week 12) in Part A

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study medication.

    Time frame: From Baseline up to Week 12 in Part A

  2. Incidents of treatment-emergent serious adverse events (TESAEs) from Baseline through the EOS Visit (Week 12) in Part A

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalisation or prolongation of existing hospitalisation * Results in persistent or significant disability/incapacity, or * Is a congenital anomaly/birth defect * Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

    Time frame: From Baseline up to Week 12 in Part A

  3. Incidents of TEAEs from Baseline through the EOS Visit (Week 22) in Part B

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study medication.

    Time frame: From Baseline up to Week 22 in Part B

  4. Incidents of TESAEs from Baseline through the EOS Visit (Week 22) in Part B

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalisation or prolongation of existing hospitalisation * Results in persistent or significant disability/incapacity, or * Is a congenital anomaly/birth defect * Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

    Time frame: From Baseline up to Week 22 in Part B

  5. ≥75% improvement vs Baseline (Yes/No) in Eczema Area and Severity Index score (EASI75) at Week 12 in Part B

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.

    Time frame: From Baseline up to Week 12 in Part B

Secondary outcomes

  1. UCB1381 Cmax from Baseline through the EOS Visit (Week 12) in Part A

    Cmax: Maximum observed concentration

    Time frame: From Baseline up to Week 12 in Part A

  2. UCB1381 Tmax from Baseline through the EOS Visit (Week 12) in Part A

    Tmax: Time of observed Cmax

    Time frame: From Baseline up to Week 12 in Part A

  3. UCB1381 AUC(0-t) from Baseline through the EOS Visit (Week 12) in Part A

    AUC(0-t): Area under the concentration-time curve from time zero to the time of last detectable concentration.

    Time frame: From Baseline up to Week 12 in Part A

  4. UCB1381 AUC from Baseline through the EOS Visit (Week 12) in Part A

    AUC: Area under the concentration-time curve from time zero to infinity.

    Time frame: From Baseline up to Week 12 in Part A

  5. UCB1381 F% from Baseline through the EOS Visit (Week 12) in Part A

    F%: Bioavailability of subcutaneous administration

    Time frame: From Baseline up to Week 12 in Part A

  6. Percent change from Baseline in EASI score at Week 12 in Part B

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.

    Time frame: From Baseline up to Week 12 in Part B

  7. ≥50% improvements vs Baseline (Yes/No) in EASI score (EASI50) at Week 12 in Part B

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.

    Time frame: From Baseline up to Week 12 in Part B

  8. ≥90% improvements vs Baseline (Y/N) in EASI score (EASI90) at Week 12 in Part B

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities The severity of disease is evaluated by assessing each of 4 clinical signs for each area: Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.

    Time frame: From Baseline up to Week 12 in Part B

  9. Validated Investigator Global Assessment (vIGA) score of 0 or 1 (Y/N) at Week 12 in Part B

    vIGA: Validated Investigator Global Assessment score is using descriptors that best describe the overall appearance of the lesions at a given time point. Assessment: vIGA 0=clear, vIGA 1=almost clear, vIGA 2=mild, vIGA 3=moderate, vIGA 4=severe

    Time frame: From Baseline up to Week 12 in Part B

  10. UCB1381 Cmax at week 12 after the final dose in Part B

    Cmax: Maximum observed concentration

    Time frame: From Baseline up to Week 12 in Part B

  11. UCB1381 Tmax at week 12 after the final dose in Part B

    Tmax: Time of observed Cmax

    Time frame: From Baseline up to Week 12 in Part B

  12. UCB1381 AUCtau at week 12 after the final dose in Part B

    AUCtau: Area under the curve for the dosing interval after the final dose.

    Time frame: From Baseline up to Week 12 in Part B

07

Study locations

16 sites
  • Up0110 125
    Beverly Hills, California 90212, United States
  • Up0110 101
    Glendale, California 91206, United States
  • Up0110 116
    Los Angeles, California 90045, United States
  • Up0110 121
    Northridge, California 91324, United States
  • Up0110 126
    Tustin, California 92780, United States
  • Up0110 127
    Valencia, California 91355, United States
  • Up0110 108
    Clearwater, Florida 33765, United States
  • Up0110 109
    Miami Lakes, Florida 33014, United States
  • Up0110 106
    Ocala, Florida 34471, United States
  • Up0110 102
    St. Petersburg, Florida 33705, United States
  • Up0110 111
    College Park, Georgia 30349, United States
  • Up0110 114
    Minneapolis, Minnesota 55455, United States
  • Up0110 107
    New York, New York 10029, United States
  • Up0110 124
    Winston-Salem, North Carolina 27103, United States
  • Up0110 104
    Oklahoma City, Oklahoma 73170, United States
  • Up0110 119
    Philadelphia, Pennsylvania 19103, United States
08

References and documents

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of reidentifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Jul 2025, 40 months.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 40 months is above that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2022
First posted
Mar 14, 2022
StartActual
Mar 7, 2022
Primary completionActual
Jul 17, 2025
CompletionActual
Sep 19, 2025
Results delay requested
Jul 16, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05277571
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Mar 14, 2022
Start date
Mar 7, 2022
Primary completion
Jul 17, 2025
Completion
Sep 19, 2025
Last update
Jul 22, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion